SERUM CANCER FROM LUNG-6: PROMISING BIOMARKER TO DIFFERENTIATE CPFE FROM IPF

Demirdöğen E., Görek Dilektaşlı A., Acet Öztürk N. A., Yeşilbursa D., Budak F., Coşkun F., ...Daha Fazla

SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, cilt.39, sa.4, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.36141/svdld.v39i4.11344
  • Dergi Adı: SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
  • Anahtar Kelimeler: Combined pulmonary fibrosis emphysema, Idiopathic pulmonary fibrosis, Krebs von den Lungen-6, Surfactant protein-A, Surfactant protein-D, Pulmonary function tests, Echocardiography, IDIOPATHIC PULMONARY-FIBROSIS, SURFACTANT PROTEIN-A, QUALITY-OF-LIFE, CIRCULATING KL-6, EMPHYSEMA, HYPERTENSION, MARKERS
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background: Combined pulmonary fibrosis and emphysema (CPFE) has been recognised as a phe-notype of pulmonary fibrosis. We aimed to compare serum surfactant protein-A (SP-A), surfactant protein-D (SP-D) and Krebs von den Lungen-6 (KL-6) levels, functional parameters, in CPFE and IPF (idiopathic pul-monary fibrosis) patients. Methods: Patients diagnosed with ???CPFE??? and ???IPF??? were consecutively included in 6 months as two groups. The patients with connective tissue diseases are excluded. Results: In this study, 47 patients (41 males, 6 females) with CPFE (n = 21) and IPF (n = 26) with a mean age of 70.12 ?? 8.75 were evaluated. CPFE patients were older, had more intense smoking history, had lower DLCO/VA, lower FVC, and worse six-minute walking distance than the IPF group (p=0.005, p=0.027, p=0.02, p<0.001, p=0.001, respec-tively). Serum KL-6 levels were higher in CPFE group compared to IPF group [264.70 U/ml (228.90-786) vs 233.60 (101.8-425.4), p<0.001]. Serum KL-6 levels of 245.4 U/ml and higher have 81% sensitivity and 73% specificity for the discrimination of CPFE from IPF. Conclusions: Our study has shown that serum KL-6 level is a promising biomarker to differentiate CPFE from IPF. In CPFE cases respiratory and functional parameters are worse than those of pure fibrosis cases.